The Vanguard Group 13D and 13G filings for Cytokinetics, Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-08 11:29 am Purchase |
2024-12-31 | 13G | Cytokinetics, Incorporated CYTK |
The Vanguard Group | 11,915,821 10.090% |
154,216 (+1.31%) |
Filing |
| 2024-11-12 2:21 pm Unchanged |
2024-09-30 | 13G | Cytokinetics, Incorporated CYTK |
The Vanguard Group | 11,761,605 9.990% |
0 (Unchanged) |
Filing |
| 2024-11-04 11:17 am Purchase |
2024-09-30 | 13G | Cytokinetics, Incorporated CYTK |
The Vanguard Group | 11,761,605 9.990% |
744,716 (+6.76%) |
Filing |
| 2024-02-13 5:02 pm Purchase |
2023-12-29 | 13G | Cytokinetics, Incorporated CYTK |
The Vanguard Group | 11,016,889 11.240% |
943,795 (+9.37%) |
Filing |
| 2023-02-09 11:16 am Purchase |
2022-12-30 | 13G | Cytokinetics, Incorporated CYTK |
The Vanguard Group | 10,073,094 10.640% |
1,331,970 (+15.24%) |
Filing |
| 2022-04-08 4:31 pm Purchase |
2022-03-31 | 13G | Cytokinetics, Incorporated CYTK |
The Vanguard Group | 8,741,124 10.300% |
1,751,405 (+25.06%) |
Filing |
| 2022-02-09 3:43 pm Purchase |
2021-12-31 | 13G | Cytokinetics, Incorporated CYTK |
The Vanguard Group | 6,989,719 8.330% |
2,167,729 (+44.96%) |
Filing |
| 2021-02-10 10:46 am Purchase |
2020-12-31 | 13G | Cytokinetics, Incorporated CYTK |
The Vanguard Group | 4,821,990 6.810% |
276,000 (+6.07%) |
Filing |